Bio-Technopark
In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On the former site of the Schweizerische Wagons- und Aufzügefabrik AG and on neighboring sites, 100,000 m2 of laboratory, production and office space is now leased to around 60 companies and organizations, and 80 academic research groups. Video
Leasing
In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with partly shared infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.
Services
The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.
News
Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025
Financial & Operational Highlights Total Medical Device sales rose by 77% to USD 101.1 million for the first nine months of 2025 (9M 2024: USD 57.2 million) Direct MagnetOs™ sales increased by 76% to USD 99.7 million for the first nine months of 2025 (9M 2024: USD 56.7 million) EBITDA...
Neurimmune begins phase 2 trial treatment
Zurich, Switzerland - 14.10.2025 Neurimmune today announced it has initiated a Phase 2 follow-on study to evaluate the pharmacodynamics and safety of cliramitug (formerly ALXN2220, NI006) for transthyretin amyloid cardiomyopathy (ATTR-CM) in patients who were previously enrolled in the proof-of-concept study NI006-101 (NCT04360434). Cliramitug is an investigational human monoclonal antibody designed to...